Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE) (PE)

Efficacy of Adding Sildenafil to Dapoxetine in Treatment of Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)

Study Design: Single Blind Placebo Controlled Randomized Trial, aiming to assess the efficacy and safety of adding sildinafile 50 mg to dapoxitine 30 mg in dapoxitine non responding premature ejaculation.

Study Overview

• Status: Not yet recruiting
• Conditions: Premature Ejaculation
• Intervention / Treatment: Drug: Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet; Drug: Placebo oral tablet and Dapoxitine 3mg Oral tablet

Detailed Description

Study Design: Single Blind, Placebo Controlled Randomized Trial.

Study Setting: Urology outpatient clinics at Al-Hussein and Sayed Galal Hospitals; Al-Azhar University; Cairo; Egypt.

Timeline: 12 months [8 months for data collection; 2 months for thesis writing and 2 months for publication].

Study Population:

• The study participants will be males suffering from primary or acquired mono-symptomatic premature ejaculation (PE) that did not respond to 2 months of dapoxetine monotherapy.
• participants will considered to have PE if they fulfilled the criteria of the International Society for Sexual Medicine that defines PE as a male sexual dysfunction characterized by (i) ejaculation which always or nearly always occurs prior to or within 1 min of vaginal penetration, either present from the first sexual experience or following a new bothersome change in ejaculatory latency. (ii) Negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy(Gillman & Gillman, 2019).
• Other patient inclusion criteria will be: age ≥20 years old, married and in a stable regular sexual relationship for at least 3 months before the study.

Exclusion criteria:

• Men with associated erectile dysfunction (ED).
• Men with associated chronic prostatitis.
• Diabetes Mellitus (DM).
• Advanced renal or hepatic diseases.
• Neurological diseases and C.N.S. medications.
• Contraindication to sildenafil as Nitric Oxide dependent ischemic heart disease patients or drug allergy.

Study Sample:

- All available cases with complete medical record and accepted follow-up with us will be included.

Study Procedures and Data Collection:

• Single blind placebo randomized controlled trial will be conducted on 200 male participants with PE divided into two groups 100 participant in each.
• The participants will be selected from those seeking medical advice at the outpatient clinics of Al-Hussein and Sayed Galal Hospitals; Al-Azhar University; Cairo; Egypt starting from October 2022.
• An informed consent will be obtained by each participant after full explanation for the nature of the research.

• The medical records of all adult males suffering from mono-symptomatic premature ejaculation who were treated with on demand dapoxetine for 2 months with no improvement and agree to participate in the study will be reviewed for,

  1. Demographic and clinical data as, age, comorbidities, occupation, parity, body mass index.
  2. Detailed medical and sexual history.
  3. All patients will be evaluated by the International Index of Erectile Function 5 (IIEF5) item questionnaires to exclude those with erectile dysfunction (score ≥22) and premature ejaculation diagnostic tool (PEDT).
  4. Physical examination including local abdominal and genital examination.
  5. Urine analysis with culture and sensitivity.
  6. Abdominopelvic ultrasonography.

  7. If needed Penile duplex US and Or Nocturnal Penile Tumescence and Rigidity (NPTR)will be performed to exclude organic ED.

     Participants of our study will be enrolled into two groups (A and B). participants enrollment will be done by simple randomization method through which none of participants know in which group he will be. Group (A) will receive sildenafil 50mg as additive therapy to dapoxetine 30 mg for 8 weeks. Group (B) will continue on dapoxetine 30mg with placebo for the same period as group (A).

     All patients will be instructed to do sexual intercourse 2-3 times a week.

• All patients were evaluated before and after the treatment by Premature Ejaculation Diagnostic Tool (PEDT) and IIEF-5, using the validated Arabic version of both questionnaires, Questionnaire will be fulfilled by face to face interview method.

Protection of Participants:

1. The research will be explained in detail to the participants before inclusion in the study.
2. Participants will sign an informed written consent before enrollment.
3. Extreme care will be taken during the research related procedures.
4. It will be made clear that the subject has the full right to withdraw from the study at any time.
5. Informed consent and all study material will be kept in separate lockers; not accessed except by study investigators.

• Study Type: Interventional
• Enrollment (Anticipated): 200
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Mohamed I Algammal, MD; Phone Number: 01000319556; Email: gemykarter2020@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Male patients, age ≥20 years old, married and/or in a stable regular sexual relationship for at least 3 months before the study.

Exclusion Criteria:

• - Men with associated erectile dysfunction (ED).
• Men with associated chronic prostatitis.
• Diabetes Mellitus (DM).
• Advanced renal or hepatic diseases.
• Neurological diseases and C.N.S. medications.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: sofenacine recievers group A; Group (A) will receive sildenafil 50mg tablet form as additive therapy to dapoxetine 30 mg tablet form on demand for 8 weeks.	Drug: Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet; Single blind placebo randomized controlled trial; Other Names: viagra; prigily
Placebo Comparator: palcebo recievers group B; Group (B) will continue on dapoxetine 30mg tablet form with placebo tablet form of the same shap and colour of sildinafile on demand for 8 weeks.	Drug: Placebo oral tablet and Dapoxitine 3mg Oral tablet; Single blind placebo randomized controlled trial

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
intravaginal latency time changes IVLT	Using PEDT premature ejaculation diagnostic tool (PEDT)	Eight weaks for each participant of both groups
overall partner satisfaction	using Sexual Satisfaction Index (SSI).	Eight weaks for each participants of both groups

Collaborators and Investigators

• Sponsor: Al-Azhar University
• Investigators: Principal Investigator: Mohamed I Algammal, MD., Urologist

Study record dates

Study Major Dates

• Study Start (Anticipated): October 1, 2022
• Primary Completion (Anticipated): September 29, 2023
• Study Completion (Anticipated): November 1, 2023

Study Registration Dates

• First Submitted: September 10, 2022
• First Submitted That Met QC Criteria: September 25, 2022
• First Posted (Actual): September 27, 2022

Study Record Updates

• Last Update Posted (Actual): September 27, 2022
• Last Update Submitted That Met QC Criteria: September 25, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: Premature ejaculation; Sildinafile; Dapoxitine
• Additional Relevant MeSH Terms: Mental Disorders; Pregnancy Complications; Obstetric Labor Complications; Sexual Dysfunctions, Psychological; Obstetric Labor, Premature; Sexual Dysfunction, Physiological; Premature Birth; Premature Ejaculation; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Urological Agents; Enzyme Inhibitors; Phosphodiesterase Inhibitors; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate
• Other Study ID Numbers: 61158m1

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No